Novel Targets that Affect High-Density Lipoprotein Metabolism: The Next Frontier

American Journal of Cardiology

Volumn 104, Issue 10 SUPPL., 2009, Pages 52E-57E

  Davidson, Michael H ^a   Rosenson, Robert S ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ABC TRANSPORTER A1; ABC TRANSPORTER G1; ANACETRAPIB; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CSL III; DALCETRAPIB; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INTERCELLULAR ADHESION MOLECULE 1; LAROPIPRANT; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINIC ACID; NITRIC OXIDE; PRAVASTATIN; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOWN REGULATION; DRUG ELUTING STENT; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INHIBITION KINETICS; INTRAVASCULAR ULTRASOUND; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER TOXICITY; MACROPHAGE; METABOLIC SYNDROME X; MONOCYTE; MONOTHERAPY; OXIDATION; PRIORITY JOURNAL; SIDE EFFECT; THICKNESS; UPREGULATION;

EID: 72049107205     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.09.020     Document Type: Article

References (35)

1. Birjmohun R.S., Hutten B.A., Kastelein J.J., and Stroes E.S. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. J Am Coll Cardiol 45 (2005) 185-197
2. LaRosa J.C., He J., and Vuppiuturi S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282; (1999) 2340-2346
3. Castelli W.P. Cholesterol and lipids in the risk of coronary heart disease: the Framingham Heart Study. Can J Cardiol 4 suppl A (1988) 5A-10A
4. National Cholesterol Education Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 106 (2002) 3143-3421
5. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs Jr. D.R., Bangdiwala S., and Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79 (1989) 8-15
6. Schwartz G.G., Olsson A.G., Szarek M., and Sasiela W.J. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care 28 (2005) 2508-2513
7. Wolfram R.M., Brewer H.B., Xue Z., Satler L.F., Pichard A.D., Kent K.M., and Waksman R. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol 98 (2006) 711-717
8. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., and Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 95 (2004) 764-772
9. Singh I.M., Shishehbor M.H., and Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298 (2007) 786-798
10. Shah P.K., Kaul S., Nilsson J., and Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 104 (2001) 2376-2383
11. Davidson M.H., and Toth P.P. High-lipoprotein metabolism: potential therapeutic targets. Am J Cardiol 100 suppl 1 (2007) S32-S40
12. Tall A.R., Yvan-Charvet L., Terasaka N., Pagler T., and Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab 7 (2008) 365-375
13. Davidson M.H. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol 98 suppl (2006) 27i-33i
14. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
15. Koren M.J., Hunninghake D.B., and ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol 44 (2004) 1772-1779
16. Brewer Jr. H.G. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 92 (2003) 23K-29K
17. Lamon-Fava S., Diffenderfer M., Barrett P.R., Buchsbaum A., Nyaku M., Horvath K.V., Asztalos B.F., Otokozawa S., Ai M., Matthan N.R., et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (apo) A-I- and apoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 28 (2008) 1672-1678
18. Lai E., De Lepeleire I., and Crumley T.M. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 81 (2007) 849-857
19. Heartwire. ACHIEVE stopped: IMT study with niacin/laropiprant halted by Merck. http://www.theheart.org/article/869153.do Accessed September 1, 2009
20. University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit. HPS2-THRIVE. http://www.ctsu.ox.ac.uk/pressreleases/2006-05-31/hps2-thrive-press-rele ase Accessed September 10, 2009
21. Rader D.A. Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism. Am J Cardiol 91 (2003) 18-23
22. Rosenson R.S. Management of non-high-density lipoprotein abnormalities. Atherosclerosis 373 (2009) 649-658
23. Toth P.P. Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. Curr Atheroscler Rep 9 (2007) 81-88
24. Brousseau M.E., Schaefer E.J., Wolfe M.L., Bloedon L.T., Digenio A.G., Clark R.W., Mancuso J.P., and Rader D.J. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004) 1505-1515
25. Barter P., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komadja M., Lopez-Sendon J., Mosca L., Tardif J.C., Waters D.D., et al., ILLUMINATE Investigators. Effects of torcetrapib on morbidity and mortality in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
26. Kastelein J.J., van Leuven S.I., Burgess L., Evans G.W., Kuivenhoven J.A., Barter P.J., Revkin J.H., Grobbee D.E., Riley W.A., Shear C.L., Duggan W.T., Bots M.L., and RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 (2007) 1620-1630
27. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., de Graaf J., Zwinderman A.H., Posma J.L., van Tol A., and Kastelein J.J. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105 (2002) 2159-2165
28. Kuivenhoven J.A., de Grooth G.J., Kawamura H., Klerkx A.H., Wilhelm F., Trip M.D., and Kastelein J.J. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 95 (2005) 1085-1088
29. Stein E., Stroes E., Steiner G., Buckley B., Capponi A., Burgess T., Niesor E., Kallend D., and Kastelein J. Safety and tolerability of dalcetrapib. Am J Cardiol 104 1 (2009) 82-91
30. Derks M., Fowler S., and Kuhlmann O. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin 25 (2009) 891-902
31. Qiu X., Mistry A., Ammirati M.J., Chrunyk B.A., Clark R.W., Cong Y., Culp J.S., Danley D.E., Freeman T.B., Geoghegan K.F., et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol 14 (2007) 106-113
32. Bloomfield D., Carlson G.L., Sapre A., Tribble D., McKenney J.M., Littlejohn III T.W., Sisk C.M., Mitchel Y., and Pasternak R.C. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 157 (2009) 352-360
33. Krishna R., Anderson M.S., Bergman A.J., Jin B., Fallon M., Cote J., Rosko K., Chavez-Eng C., Lutz R., Bloomfield D.M., et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 370 (2008) 1907-1914
34. Krishna R., Bergman A.J., Jin B., Garg A., Roadcap B., Chiou R., Dru J., Cote J., Laethem T., Wang R.W., et al. Assessment of the CYP31-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers. J Clin Pharmacol 49 (2009) 80-87
35. Tardif J.C., Gregoire J., L'Allier P.L., Ibrahim R., Lesperance J., Heinonen T.M., Kouz S., Berry C., Basser R., Lavoie M.A., Guertin M.C., and Rodes-Cabau J. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 (2007) 1675-1682